As precision therapy continues to progress, targeted agents, including cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is), PI3K/AKT/mTOR(PAM) inhibitors, HER2 inhibitors, vascular endothelial growth factor (VEGF) inhibitors, and histone deacetylase inhibitors (HDACis), are being combined with endocrine drug therapy to improve tumor prognosis. This evidence concerns the gene ERBB2 and neoplasm.